Congenital Glaucoma: Comprehensive Disease-Characteristics Report

Scope and evidence conventions

“Congenital glaucoma” is sometimes used broadly for glaucoma recognized at or shortly after birth. This report focuses on primary congenital glaucoma (PCG)—the Mendelian, nonsyndromic developmental glaucoma that usually manifests by age 3—and distinguishes it from secondary childhood glaucoma caused by anterior-segment anomalies, systemic syndromes, acquired disease, or cataract surgery. Evidence is aggregated at disease/cohort level; it is not derived from an individual EHR. Mechanistic evidence is labeled as human, animal, or in vitro where appropriate.

The compact curation summary below complements the narrative report.

Table: This table condenses the highest-yield disease characteristics for primary congenital glaucoma, including identifiers, genetics, mechanism, diagnosis, management, and models. It is designed as a compact curation aid and flags where ontology metadata or mechanistic interpretations should be verified before database ingestion.

1. Disease information

Definition and classification

PCG is a severe developmental optic neuropathy caused by malformed aqueous-humor outflow structures. Impaired drainage raises intraocular pressure (IOP), stretching the compliant infant eye and producing corneal enlargement, buphthalmos, and ultimately retinal ganglion-cell/optic-nerve injury. PCG is defined clinically by onset in early childhood—typically birth to age 3—without another ocular or systemic disorder sufficient to explain the glaucoma. Most children present within the first 6 months. The Childhood Glaucoma Research Network classifies PCG under primary childhood glaucoma, separate from juvenile open-angle glaucoma and secondary childhood glaucomas. (alsaei2024increasingthediagnostic pages 1-2, pan2024exploringthegenetic pages 1-2, mandal2023approachtoprimary pages 2-3)

Identifiers and synonyms

Suggested current metadata are MONDO:0018110, OMIM 231300/GLC3A, ORPHA:98976, ICD-10-CM Q15.0, and MeSH D005901. These identifiers should be checked against the release used by the target knowledge base because terminology mappings change and the retrieved primary papers did not independently establish every identifier. Common names are primary congenital glaucoma, congenital glaucoma, infantile glaucoma, trabeculodysgenesis-associated glaucoma, and historically hydrophthalmos/buphthalmos. “Buphthalmos” properly describes the enlarged globe, not the entire disease.

2. Etiology, risk, and protective factors

Causal factors

PCG is primarily genetic and developmental. The strongest genes are CYP1B1 and LTBP2 (usually autosomal recessive) and TEK and ANGPT1 (usually autosomal dominant). FOXC1 can produce developmental glaucoma or an overlapping anterior-segment dysgenesis phenotype. CYP1B1 is the predominant known cause, but its contribution varies markedly by ancestry: a 2024 systematic review found reported CYP1B1 prevalence of approximately 5–86% across PCG populations. In the 100,000 Genomes childhood-glaucoma cohort, CYP1B1 accounted for 55% of molecularly solved families. (alsaei2024increasingthediagnostic pages 1-2, pan2024exploringthegenetic pages 11-12)

Genetic risk and modifiers

Consanguinity and an affected sibling or parent are major risk indicators. Only about 10–40% of PCG is reported as familial, however, so absence of family history does not exclude a Mendelian cause. TEK disease shows incomplete penetrance and variable expressivity; SVEP1 has experimental and familial evidence as a modifier of TEK expression and disease severity. Possible digenic/modifier relationships involving CYP1B1 with MYOC or TEK have been proposed but are not established as routine diagnostic models. (alsaei2024increasingthediagnostic pages 1-2, pan2024exploringthegenetic pages 11-12, pan2024exploringthegenetic pages 14-15)

Pathogenic alleles include missense, nonsense, frameshift, splice, deletion/CNV, and other loss-of-function variants. The relevant origin is germline, not somatic. Truly pathogenic recessive alleles are generally rare in population databases; no universal carrier frequency is appropriate because founder alleles and consanguinity create strong population differences. Variant-specific gnomAD frequency and ClinVar/ACMG classification should therefore be stored rather than a single disease-wide frequency.

Environmental, lifestyle, infectious, and protective factors

No toxin, infection, diet, smoking behavior, or occupational exposure is accepted as a primary cause of isolated PCG. Environmental epidemiology is sparse and does not support actionable lifestyle prevention. The main “protective” factors are not biologic alleles or exposures, but early recognition, prompt IOP-lowering surgery, refractive correction, amblyopia treatment, and sustained follow-up, which reduce preventable visual loss. Evidence for clinically meaningful gene–environment interaction or protective variants remains insufficient.

3. Phenotypes

The characteristic symptom triad is epiphora, photophobia, and blepharospasm. Signs include corneal edema/haze, enlarged corneal diameter, horizontal Descemet-membrane breaks (Haab striae), buphthalmos, elevated IOP, progressive axial elongation/myopia, optic-disc cupping, rim loss, and later visual-field or visual-acuity loss. PCG is bilateral in approximately 70%, but severity is often asymmetric. (mandal2023approachtoprimary pages 2-3)

Suggested phenotype terms include epiphora (HP:0000627), photophobia (HP:0000613), blepharospasm (HP:0000652), corneal edema (HP:0007957), buphthalmos (HP:0001083), myopia (HP:0000541), increased IOP (HP:0000628), abnormal optic disc (HP:0000598), and increased cup-to-disc ratio (HP:0007686). Exact HPO identifiers and preferred labels should be validated before ingestion.

Severity is variable and progressive without treatment. Corneal enlargement is particularly useful in infants: normal horizontal diameter is about 10 mm at birth; concerning thresholds include ≥11 mm in a newborn, >12 mm before age 1, and >13 mm at any age. Symptoms, repeated anesthesia, spectacles/contact lenses, amblyopia treatment, surgery, and fear of blindness affect both child and caregiver quality of life. Better visual acuity correlates with better quality of life, but validated PCG-specific patient-reported outcome data remain limited. (mandal2023approachtoprimary pages 2-3, coviltir2025primarycongenitaland pages 1-2)

4. Genetic and molecular information

• CYP1B1: cytochrome-P450 monooxygenase; principally biallelic loss of function. More than 200 variants have been reported. Missense changes may impair heme binding, folding, stability, or catalytic activity; truncating/splice alleles usually abolish function. Human genetic evidence is strong.
• LTBP2: biallelic loss-of-function alleles disrupt extracellular microfibrils and ciliary-zonule/outflow architecture; association with TGF-β-related extracellular-matrix biology is plausible, although LTBP2 does not simply function as a conventional latent-TGF-β carrier in every context. Human genetic and mouse evidence support causality.
• TEK/TIE2 and ANGPT1: heterozygous loss-of-function/haploinsufficiency impairs angiopoietin–TEK signaling required for Schlemm-canal endothelial development. Penetrance is incomplete and expressivity variable.
• FOXC1: heterozygous dosage or functional defects impair neural-crest/periocular-mesenchyme programs and anterior-segment formation. FOXC1 more often causes an anterior-segment dysgenesis spectrum, including Axenfeld–Rieger phenotypes, than strictly isolated PCG.
• SVEP1: candidate modifier of TEK-related penetrance/severity, not an independently validated common PCG gene. (pan2024exploringthegenetic pages 14-15, pan2024exploringthegenetic pages 7-9, gomez2020establishingzebrafishdanio pages 46-51)

A 2024 Japanese study found CYP1B1 variants in 9 of 29 childhood-glaucoma families, including novel p.A202T, p.D274E, p.Q340, and p.V420G, and novel heterozygous FOXC1 variants p.Q23fs, p.Q70R, and p.E163. The observations illustrate population specificity and the need for ACMG/AMP assessment rather than assuming pathogenicity from novelty alone.

No reproducible PCG-specific methylation, histone, repeat-expansion, mitochondrial, or somatic-mutation mechanism is established. Large FOXC1 CNVs can be causal, so copy-number analysis should not be omitted. In the 100,000 Genomes study, expanded analysis increased solved families from 17% to 26%, identifying missed TEK variants and a pathogenic FOXC1 CNV; smaller panels and prioritization of coding SNVs/indels had missed structural, CNV, and noncoding candidates. (alsaei2024increasingthediagnostic pages 1-2)

5. Mechanism and pathophysiology

The principal causal chain is:

developmental gene defect → trabecular-meshwork/Schlemm-canal dysgenesis → increased aqueous outflow resistance → elevated IOP → infant globe and corneal stretching → buphthalmos, Haab striae, edema, axial myopia → retinal ganglion-cell axonal injury and optic-nerve cupping → irreversible visual-field and acuity loss.

CYP1B1 appears upstream in fetal trabecular-meshwork development, oxidative homeostasis, extracellular-matrix regulation, and metabolism of endogenous retinoids, steroids, arachidonate, and melatonin. Cyp1b1-deficient mice develop abnormal trabecular meshwork and Schlemm canal and greater susceptibility to pressure-induced axonopathy. (vasiliou2008roleofcyp1b1 pages 1-2, pan2024exploringthegenetic pages 2-4)

TEK is expressed by Schlemm-canal endothelium; ANGPT1 promotes TEK activation, endothelial survival, and vessel stability. Conditional Tek or angiopoietin deletion in mice causes canal loss, ocular hypertension, and rapid retinal ganglion-cell injury. One model reported IOP of 35.58 ±2.01 mmHg after combined angiopoietin deletion versus 23.53 ±1.50 mmHg with Angpt1 deletion alone. This is animal-model evidence, not a human clinical threshold. (pan2024exploringthegenetic pages 7-9)

Relevant suggested processes are extracellular-matrix organization (GO:0030198), response to oxidative stress (GO:0006979), endothelial development/angiogenesis (GO:0001525), neural-crest development, aqueous-humor outflow, and retinal ganglion-cell death. Relevant cells are trabecular-meshwork cells, Schlemm-canal endothelial cells, neural-crest-derived periocular mesenchyme, corneal endothelial cells, and retinal ganglion cells. Exact CL identifiers should be validated.

No validated clinical metabolomic, lipidomic, proteomic, single-cell, spatial-transcriptomic, or integrated multi-omic signature currently diagnoses PCG. Zebrafish transcriptomics implicates extracellular matrix, adhesion, proliferation, lipid/retinoid metabolism, oxidation–reduction, and inflammation, but translation to human disease remains uncertain. (pan2024exploringthegenetic pages 14-15, gomez2020establishingzebrafishdanio pages 46-51)

6–7. Anatomy and localization

The primary organ is the eye, especially the iridocorneal angle, trabecular meshwork, Schlemm canal, cornea, sclera, anterior chamber, optic nerve head, retina, and retinal ganglion-cell axons. Suggested anatomy terms include trabecular meshwork (UBERON:0001769), cornea (UBERON:0000964; verify release), retina (UBERON:0000966), and optic nerve (UBERON:0001780). Subcellular dysfunction can involve CYP1B1-associated endoplasmic-reticulum/microsomal enzyme activity and nuclear FOXC1 transcriptional regulation. Disease is usually bilateral but asymmetric; no consistent right/left preference is known. There is ordinarily no direct extraocular organ involvement in isolated PCG.

8–9. Temporal development, inheritance, and population epidemiology

Onset is congenital or infantile, usually insidious and progressive. Untreated disease does not remit spontaneously. Early stages feature tearing, photophobia, corneal haze, and IOP elevation; intermediate disease produces globe enlargement, Haab striae, myopia, and optic cupping; advanced disease causes corneal scarring, profound optic neuropathy, amblyopia, and irreversible blindness.

Reported frequency varies from roughly 1 per 10,000–68,000 in Western populations to approximately 1:2,500 in Saudi Arabia, 1:8,200 in Palestinian Arabs, and 1:1,250 in Slovakian Roma, largely reflecting founder effects and consanguinity. Males are slightly overrepresented in many sporadic cohorts, whereas familial cases may approach equal sex distribution. PCG contributes about 5–18% of childhood blindness in published syntheses. (coviltir2025primarycongenitaland pages 2-4, mandal2023approachtoprimary pages 2-3, coviltir2025primarycongenitaland pages 1-2)

CYP1B1/LTBP2 disease implies a 25% recurrence risk for each pregnancy when both parents are confirmed carriers. TEK/ANGPT1/FOXC1 disease can imply a 50% transmission risk from a heterozygous parent, modified by incomplete penetrance and variable expressivity. Anticipation is not established. Germline mosaicism is theoretically possible but not a defining feature. Founder effects and consanguinity are important; carrier frequency must be calculated for the relevant population and variant.

10. Diagnostics

Clinical evaluation

A complete examination—often under anesthesia—includes tonometry, horizontal corneal diameter, pachymetry where feasible, corneal inspection, gonioscopy, axial length/refraction, dilated optic-nerve examination, and serial photography or OCT when technically possible. An accepted CGRN-style diagnosis requires childhood glaucoma with at least two findings such as IOP >21 mmHg, optic-nerve cupping/asymmetry or rim thinning, progressive myopia/axial enlargement, corneal enlargement/edema/Haab striae, or reproducible visual-field loss. (coviltir2025primarycongenitaland pages 2-4, mandal2023approachtoprimary pages 2-3)

Differential diagnoses include isolated megalocornea, keratoglobus, birth-trauma Descemet tears, Peters anomaly, sclerocornea, congenital hereditary endothelial dystrophy, mucopolysaccharidosis, optic-nerve hypoplasia, retinoblastoma-associated glaucoma, steroid/uveitic glaucoma, and glaucoma associated with aniridia, Axenfeld–Rieger syndrome, Sturge–Weber syndrome, or congenital cataract surgery. (coviltir2025primarycongenitaland pages 1-2)

Genetic testing

Recommended testing begins with a childhood-glaucoma/anterior-segment panel containing at least CYP1B1, LTBP2, TEK, ANGPT1, and FOXC1, with deletion/duplication analysis. Broader genes should be included when syndromic or anterior-segment findings are present. If negative, trio WES or preferably WGS with CNV, structural, splice, and noncoding analysis is reasonable. CMA is useful when developmental delay, congenital anomalies, or suspected chromosomal imbalance accompanies glaucoma. Karyotype/FISH are targeted tests, not routine first-line assays. Mitochondrial and repeat-expansion testing are not generally indicated. (alsaei2024increasingthediagnostic pages 1-2, pan2024exploringthegenetic pages 11-12)

No biochemical blood test or liquid-biopsy biomarker confirms PCG. Cascade examination and variant testing are appropriate for relatives after a molecular diagnosis. Population newborn biochemical screening is not available.

11. Outcomes and prognosis

PCG does not materially shorten life expectancy; morbidity is visual. Reported stationary disease declined from 90.3% at 1 year to 70.8% at 10 years and 58.3% at 34 years, demonstrating the need for lifelong surveillance. Median better-eye visual acuity of 20/30 has been reported in appropriately managed cohorts, but severe bilateral impairment remains possible. Angle-surgery success was approximately 90% for presentation at 2–12 months versus 50% in later-onset cases in one synthesis. Prognosis worsens with advanced corneal enlargement/scarring, severe initial optic neuropathy, delayed surgery, uncontrolled IOP, repeated operations, anisometropia/amblyopia, and poor follow-up. (coviltir2025primarycongenitaland pages 10-11)

12. Treatment and current implementation

Surgery is definitive first-line treatment. Clear corneas commonly permit goniotomy; trabeculotomy, including circumferential microcatheter/suture techniques, bypasses limited gonioscopic visibility. Severe edematous/megalocornea presentations in India and the Middle East are often treated with combined trabeculotomy–trabeculectomy, sometimes with mitomycin C. Refractory disease may require trabeculectomy, a glaucoma drainage device, or repeat angle surgery. Cyclophotocoagulation is usually reserved for advanced or poor-visual-potential eyes. (coviltir2025primarycongenitaland pages 2-4, mandal2023approachtoprimary pages 2-3)

Topical beta-blockers, carbonic-anhydrase inhibitors, prostaglandin analogues, and selected other agents are bridges to surgery or adjuncts afterward, not cures for dysgenesis. Drug choice requires pediatric systemic-safety attention. Optical correction, amblyopia therapy, corneal care, low-vision rehabilitation, educational support, and caregiver counseling are essential.

Real-world trials include completed microcatheter circumferential trabeculotomy (NCT04116450, 25 eyes), randomized circumferential suture trabeculotomy versus rigid-probe viscotrabeculotomy (NCT04683289, 51 participants), and Ologen-assisted versus unaugmented combined trabeculotomy–trabeculectomy (NCT03541551, 44 participants). Another 40-participant study compared nonpenetrating deep sclerectomy with combined trabeculotomy–trabeculectomy (NCT06189326). These studies use IOP control, medication burden, corneal diameter, axial length, cup-to-disc ratio, and complications as outcomes. (NCT04116450 chunk 1, NCT03541551 chunk 1, NCT04683289 chunk 1, NCT06189326 chunk 1)

No approved gene, cell, RNA, or genotype-directed pharmacologic therapy currently corrects PCG. Pharmacogenomic prescribing standards are unavailable.

Suggested NCIT intervention concepts are goniotomy, trabeculotomy, trabeculectomy, glaucoma drainage-device implantation, cyclophotocoagulation, mitomycin C, refraction correction, and low-vision rehabilitation; exact NCIT codes should be release-validated.

13. Prevention

There is no vaccine or lifestyle-based primary prevention. For known familial disease, genetic counseling should cover inheritance, penetrance, recurrence, carrier/cascade testing, and locally available prenatal or preimplantation genetic testing. At-risk newborns require early ophthalmic examination even if asymptomatic. Secondary prevention consists of caregiver/professional education about tearing, light sensitivity, eyelid squeezing, corneal haze, or an enlarging eye and urgent referral. Tertiary prevention comprises durable IOP control, amblyopia treatment, refractive correction, protection of the better eye, and lifelong monitoring.

14–15. Other species and models

Naturally occurring congenital glaucoma is reported in veterinary medicine, particularly in some dog breeds, but the retrieved evidence did not support reliable breed/VBO, variant, or incidence annotations; these should not be populated without an OMIA/veterinary-specific review. PCG is noninfectious and has no zoonotic transmission.

Mouse models provide the strongest mechanistic validation. Cyp1b1-null mice show trabecular-meshwork/Schlemm-canal abnormalities and oxidative-stress susceptibility; conditional Tek or Angpt deletion produces Schlemm-canal loss, ocular hypertension, buphthalmos, and retinal ganglion-cell injury. Zebrafish cyp1b1 knockout is useful for developmental and transcriptomic studies but does not faithfully reproduce glaucoma: adult craniofacial defects showed incomplete penetrance, and no glaucoma phenotype was observed. Thus it is a pathway model rather than a complete phenocopy. (pan2024exploringthegenetic pages 14-15, pan2024exploringthegenetic pages 7-9, gomez2020establishingzebrafishdanio pages 46-51, vasiliou2008roleofcyp1b1 pages 1-2)

Recent 2023–2024 developments and expert assessment

The most consequential recent development is improved genome interpretation rather than a new therapy. The 2024 100,000 Genomes reanalysis showed that expanding gene lists and interrogating CNVs, structural variants, and noncoding regions increased diagnostic yield to 26%, while a 2024 systematic review identified 53 genes discussed across childhood-glaucoma literature and emphasized the absence of standardized testing guidelines. (alsaei2024increasingthediagnostic pages 1-2, pan2024exploringthegenetic pages 11-12)

Exploratory deep-learning analysis of gaze photographs achieved reported sensitivity 0.85 and specificity 0.94, but external validation and evaluation across ancestries, ages, corneal opacity, and imaging devices are required before population screening. (coviltir2025primarycongenitaland pages 1-2)

The prevailing expert position is that rapid clinical recognition and surgery remain more immediately vision-saving than molecular diagnosis, while genomic testing adds value for etiologic classification, recurrence counseling, detecting syndromic disease, and future precision trials. Major research gaps are unsolved families, penetrance modifiers, validated functional assays for variants of uncertain significance, standardized patient-reported outcomes, prospective comparative surgery trials, and human single-cell/spatial characterization of the developing outflow tract.

Selected recent sources and abstract-supported statements

• Al-Saei et al., BMC Genomics, May 2024, DOI: https://doi.org/10.1186/s12864-024-10353-8. Abstract: “This analysis effectively raises the total number of solved CG families in the GE100KGP to 26%.” (alsaei2024increasingthediagnostic pages 1-2)
• Pan and Iwata, Children, April 2024, DOI: https://doi.org/10.3390/children11040454. The review identifies CYP1B1, LTBP2, TEK, ANGPT1, and FOXC1 as central PCG genes and integrates relevant animal pathways. (pan2024exploringthegenetic pages 11-12, pan2024exploringthegenetic pages 7-9)
• Mandal et al., Taiwan Journal of Ophthalmology, October 2023, DOI: https://doi.org/10.4103/tjo.tjo-d-23-00104. Abstract: “Medical therapy only serves as a supportive role, and surgical intervention remains the principal therapeutic modality.” (mandal2023approachtoprimary pages 2-3)
• Kumar et al., PLOS ONE, February 2024, DOI: https://doi.org/10.1371/journal.pone.0298883. The systematic review screened 1,916 records, included 196 studies, and found that CYP1B1 prevalence varied by region and population. (pan2024exploringthegenetic pages 11-12)

PMIDs were not consistently present in the retrieved full-text metadata; DOI URLs are therefore supplied rather than risking incorrect PMID assignment.

References

1. (alsaei2024increasingthediagnostic pages 1-2): Omayma Al-Saei, Samantha Malka, Nicholas Owen, Elbay Aliyev, Fazulur Rehaman Vempalli, Paulina Ocieczek, Bashayer Al-Khathlan, Khalid Fakhro, and Mariya Moosajee. Increasing the diagnostic yield of childhood glaucoma cases recruited into the 100,000 genomes project. BMC Genomics, May 2024. URL: https://doi.org/10.1186/s12864-024-10353-8, doi:10.1186/s12864-024-10353-8. This article has 5 citations and is from a peer-reviewed journal.

2. (pan2024exploringthegenetic pages 1-2): Yang Pan and Takeshi Iwata. Exploring the genetic landscape of childhood glaucoma. Children, 11:454, Apr 2024. URL: https://doi.org/10.3390/children11040454, doi:10.3390/children11040454. This article has 18 citations.

3. (mandal2023approachtoprimary pages 2-3): Anil Kumar Mandal, Debasis Chakrabarti, and Vijaya K. Gothwal. Approach to primary congenital glaucoma: a perspective. Oct 2023. URL: https://doi.org/10.4103/tjo.tjo-d-23-00104, doi:10.4103/tjo.tjo-d-23-00104. This article has 22 citations.

4. (coviltir2025primarycongenitaland pages 2-4): Valeria Coviltir, Maria Cristina Marinescu, Bianca Maria Urse, and Miruna Gabriela Burcel. Primary congenital and childhood glaucoma—a complex clinical picture and surgical management. Diagnostics, 15:308, Jan 2025. URL: https://doi.org/10.3390/diagnostics15030308, doi:10.3390/diagnostics15030308. This article has 13 citations.

5. (coviltir2025primarycongenitaland pages 1-2): Valeria Coviltir, Maria Cristina Marinescu, Bianca Maria Urse, and Miruna Gabriela Burcel. Primary congenital and childhood glaucoma—a complex clinical picture and surgical management. Diagnostics, 15:308, Jan 2025. URL: https://doi.org/10.3390/diagnostics15030308, doi:10.3390/diagnostics15030308. This article has 13 citations.

6. (pan2024exploringthegenetic pages 11-12): Yang Pan and Takeshi Iwata. Exploring the genetic landscape of childhood glaucoma. Children, 11:454, Apr 2024. URL: https://doi.org/10.3390/children11040454, doi:10.3390/children11040454. This article has 18 citations.

7. (pan2024exploringthegenetic pages 14-15): Yang Pan and Takeshi Iwata. Exploring the genetic landscape of childhood glaucoma. Children, 11:454, Apr 2024. URL: https://doi.org/10.3390/children11040454, doi:10.3390/children11040454. This article has 18 citations.

8. (pan2024exploringthegenetic pages 7-9): Yang Pan and Takeshi Iwata. Exploring the genetic landscape of childhood glaucoma. Children, 11:454, Apr 2024. URL: https://doi.org/10.3390/children11040454, doi:10.3390/children11040454. This article has 18 citations.

9. (gomez2020establishingzebrafishdanio pages 46-51): Jurgienne Arizza Gomez Umali. Establishing zebrafish, danio rerio, as a genetic model for glaucoma. Text, 2020. URL: https://doi.org/10.48336/k82g-gr50, doi:10.48336/k82g-gr50. This article has 0 citations and is from a peer-reviewed journal.

10. (vasiliou2008roleofcyp1b1 pages 1-2): Vasilis Vasiliou and Frank J. Gonzalez. Role of cyp1b1 in glaucoma. Annual Review of Pharmacology and Toxicology, 48:333-358, Feb 2008. URL: https://doi.org/10.1146/annurev.pharmtox.48.061807.154729, doi:10.1146/annurev.pharmtox.48.061807.154729. This article has 268 citations and is from a highest quality peer-reviewed journal.

11. (pan2024exploringthegenetic pages 2-4): Yang Pan and Takeshi Iwata. Exploring the genetic landscape of childhood glaucoma. Children, 11:454, Apr 2024. URL: https://doi.org/10.3390/children11040454, doi:10.3390/children11040454. This article has 18 citations.

12. (NCT04116450 chunk 1): Shaaban Elwan. MicrocatheterTrabeculotomy in Primary Congenital Glaucoma. Minia University. 2017. ClinicalTrials.gov Identifier: NCT04116450

13. (NCT03541551 chunk 1): HERF. Ologen® Collagen Matrix in Patients With Primary Congenital Glaucoma Undergoing Trabeculectomy. L.V. Prasad Eye Institute. 2018. ClinicalTrials.gov Identifier: NCT03541551

14. (NCT04683289 chunk 1): Visco-Circumferential-Suture-Trabeculotomy Versus Trabeculotomy. Mansoura University. 2015. ClinicalTrials.gov Identifier: NCT04683289

15. (NCT06189326 chunk 1): Ehab Tharwat. Non-penetrating Deep Sclerectomy Versus Trabeculotomy- Trabeculectomy Operation in Treatment of Primary Congenital Glaucoma. Al-Azhar University. 2022. ClinicalTrials.gov Identifier: NCT06189326

16. (coviltir2025primarycongenitaland pages 10-11): Valeria Coviltir, Maria Cristina Marinescu, Bianca Maria Urse, and Miruna Gabriela Burcel. Primary congenital and childhood glaucoma—a complex clinical picture and surgical management. Diagnostics, 15:308, Jan 2025. URL: https://doi.org/10.3390/diagnostics15030308, doi:10.3390/diagnostics15030308. This article has 13 citations.

Artifacts

• Edison artifact artifact-00

Reference Validation

Checked with linkml-reference-validator 0.2.1.

All extracted references resolved successfully.